HGNS Vendors Plan Response to Plunging Stock Valuations
The neuromodulation market for treating obstructive sleep apnea is currently experiencing a transitional rough patch, though its long-term market potential remains robust. Nominally represented by Inspire Medical, Nyxoah, and LivaNova, the market has seen staggered timelines of adoption. Inspire has been commercializing its devices in the U.S. since 2014, whereas Nyxoah entered in 2025, and LivaNova is targeting a full market launch in the second half of 2027.